Assessment of drug-related migraine in a real-world large-scale database
BackgroundDrug-induced migraine represents a clinically significant yet under-investigated subtype of migraine. This study aims to evaluate the risk of drug-related migraine based on real-world data from the FDA Adverse Event Reporting System (FAERS).MethodsA retrospective pharmacovigilance analysis...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1647088/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849419273593683968 |
|---|---|
| author | Fan Wu Ao Liu Zhenyuan Jiang Zhonglin Wang |
| author_facet | Fan Wu Ao Liu Zhenyuan Jiang Zhonglin Wang |
| author_sort | Fan Wu |
| collection | DOAJ |
| description | BackgroundDrug-induced migraine represents a clinically significant yet under-investigated subtype of migraine. This study aims to evaluate the risk of drug-related migraine based on real-world data from the FDA Adverse Event Reporting System (FAERS).MethodsA retrospective pharmacovigilance analysis was conducted using FAERS data from Q1 2004 to Q4 2024. Migraine cases were identified via standardized MedDRA (The Medical Dictionary for Regulatory Activities) terms. Only primary suspect drugs were included. Disproportionality analyses were performed using four algorithms: ROR, PRR, MGPS, and BCPNN. Drugs were classified by therapeutic indication and mechanism of action, and stratified by BCPNN values to assess risk levels.ResultsA total of 20,886 migraine-related adverse events were identified, predominantly among females (77.4%) with a mean age of 45.7 years. Sixty-six drugs yielded positive signals, and after exclusion criteria, 39 remained for further analysis. The highest-risk agents included lorcaserin (BCPNN = 3.33), tasimelteon (3.20), and botulinum toxin type A (3.06). High-risk therapeutic classes included immunosuppressants, estrogens/progestogens, and sedative-hypnotics.ConclusionThis large-scale analysis identifies key drug categories and compounds associated with an elevated risk of migraine, providing actionable insights for clinicians. Especially lorcaserin, tasimelteon, and botulinum toxin as potential risk factors for migraine. Given the public health burden of migraine, pharmacovigilance efforts should incorporate such findings to mitigate iatrogenic risks. Further prospective studies are warranted to establish causal mechanisms and optimize therapeutic decision-making. |
| format | Article |
| id | doaj-art-75b424b2bf2d40138a6fccf1dac90030 |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-75b424b2bf2d40138a6fccf1dac900302025-08-20T03:32:11ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-07-011610.3389/fphar.2025.16470881647088Assessment of drug-related migraine in a real-world large-scale databaseFan Wu0Ao Liu1Zhenyuan Jiang2Zhonglin Wang3Shandong University of Traditional Chinese Medicine, Jinan, Shandong, ChinaShanghai Academy of Social Sciences, Shanghai, ChinaAffiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, ChinaShandong University of Traditional Chinese Medicine, Jinan, Shandong, ChinaBackgroundDrug-induced migraine represents a clinically significant yet under-investigated subtype of migraine. This study aims to evaluate the risk of drug-related migraine based on real-world data from the FDA Adverse Event Reporting System (FAERS).MethodsA retrospective pharmacovigilance analysis was conducted using FAERS data from Q1 2004 to Q4 2024. Migraine cases were identified via standardized MedDRA (The Medical Dictionary for Regulatory Activities) terms. Only primary suspect drugs were included. Disproportionality analyses were performed using four algorithms: ROR, PRR, MGPS, and BCPNN. Drugs were classified by therapeutic indication and mechanism of action, and stratified by BCPNN values to assess risk levels.ResultsA total of 20,886 migraine-related adverse events were identified, predominantly among females (77.4%) with a mean age of 45.7 years. Sixty-six drugs yielded positive signals, and after exclusion criteria, 39 remained for further analysis. The highest-risk agents included lorcaserin (BCPNN = 3.33), tasimelteon (3.20), and botulinum toxin type A (3.06). High-risk therapeutic classes included immunosuppressants, estrogens/progestogens, and sedative-hypnotics.ConclusionThis large-scale analysis identifies key drug categories and compounds associated with an elevated risk of migraine, providing actionable insights for clinicians. Especially lorcaserin, tasimelteon, and botulinum toxin as potential risk factors for migraine. Given the public health burden of migraine, pharmacovigilance efforts should incorporate such findings to mitigate iatrogenic risks. Further prospective studies are warranted to establish causal mechanisms and optimize therapeutic decision-making.https://www.frontiersin.org/articles/10.3389/fphar.2025.1647088/fullmigrainedrug-induced headacheFAERSpharmacovigilancedisproportionality analysisBCPNN |
| spellingShingle | Fan Wu Ao Liu Zhenyuan Jiang Zhonglin Wang Assessment of drug-related migraine in a real-world large-scale database Frontiers in Pharmacology migraine drug-induced headache FAERS pharmacovigilance disproportionality analysis BCPNN |
| title | Assessment of drug-related migraine in a real-world large-scale database |
| title_full | Assessment of drug-related migraine in a real-world large-scale database |
| title_fullStr | Assessment of drug-related migraine in a real-world large-scale database |
| title_full_unstemmed | Assessment of drug-related migraine in a real-world large-scale database |
| title_short | Assessment of drug-related migraine in a real-world large-scale database |
| title_sort | assessment of drug related migraine in a real world large scale database |
| topic | migraine drug-induced headache FAERS pharmacovigilance disproportionality analysis BCPNN |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1647088/full |
| work_keys_str_mv | AT fanwu assessmentofdrugrelatedmigraineinarealworldlargescaledatabase AT aoliu assessmentofdrugrelatedmigraineinarealworldlargescaledatabase AT zhenyuanjiang assessmentofdrugrelatedmigraineinarealworldlargescaledatabase AT zhonglinwang assessmentofdrugrelatedmigraineinarealworldlargescaledatabase |